MedTrace Logo

Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study

NCT01287351 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82903

Last updated 2013-08-05

No results posted yet for this study

Summary

This study will compare the absolute and relative effectiveness and cost-effectiveness of asthma management in patients in the USA on inhaled corticosteroid (ICS) maintenance therapy as HFA-BDP (Qvar®) pressurised metered dose inhaler (pMDI) compared with fluticasone propionate (FP) pMDI. .

Conditions

Interventions

DRUG

extra-fine hydrofluoroalkane beclometasone dipropionate

DRUG

Fluticasone propionate

Sponsors & Collaborators

  • i3 Research

    collaborator INDUSTRY

  • Teva Branded Pharmaceutical Products R&D, Inc.

    collaborator INDUSTRY

  • Research in Real-Life Ltd

    lead NETWORK

Eligibility

Min Age
5 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2008-12-31
Completion
2010-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01287351 on ClinicalTrials.gov